Zeynep Irem Ozay, Postdoctoral Research Fellow at Huntsman Cancer Institute, shared an article she and her colleagues authored on X:
“Just in JAMA Network Open.
Real world Treatment data from >8500 patients with mRCC kidney cancer.
After 2018, only 38% and 14% of patients received 2nd and 3rd line treatment respectively.
Thanks to my mentors.”
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US
Authors: Zeynep Irem Ozay et al.
